Research Paper Volume 16, Issue 6 pp 5545—5566
A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses
Figure 9. Immunotherapy efficacy prediction. (A–D) IPS comparisons between the two risk categories. (E) Submap analysis between the different groups. (F–I) The differential expression of four model genes between response and non-response groups. (J) Comparisons of the risk score in different responses to anti-PD-1/L1 immunotherapy in IMvigor210 cohort. (K) Differences in risk score between the response and non-response groups in the IMvigor210 cohort.